These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
23. A clinical development paradigm for cancer vaccines and related biologics. Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G; J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079 [TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic vaccines for prostate cancer: a review of clinical data. Arlen PM; Gulley JL Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910 [TBL] [Abstract][Full Text] [Related]
26. Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax. Motl SE Curr Opin Mol Ther; 2004 Feb; 6(1):104-11. PubMed ID: 15011788 [TBL] [Abstract][Full Text] [Related]
27. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]. Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874 [TBL] [Abstract][Full Text] [Related]
28. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. North SA; Graham K; Bodnar D; Venner P J Urol; 2006 Jul; 176(1):91-5. PubMed ID: 16753376 [TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2). Acres B J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281 [TBL] [Abstract][Full Text] [Related]
30. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Lubaroff DM; Konety B; Link BK; Ratliff TL; Madsen T; Shannon M; Ecklund D; Williams RD Hum Gene Ther; 2006 Feb; 17(2):220-9. PubMed ID: 16454655 [No Abstract] [Full Text] [Related]
36. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. Minev BR; Guo F; Gueorguieva I; Kaiser HE In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883 [TBL] [Abstract][Full Text] [Related]
37. Current immunotherapeutic strategies in prostate cancer. Grosso JF; Drake CG Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549 [TBL] [Abstract][Full Text] [Related]
38. A year of successful cancer vaccines points to a path forward. Morse MA; Whelan M Curr Opin Mol Ther; 2010 Feb; 12(1):11-3. PubMed ID: 20140811 [TBL] [Abstract][Full Text] [Related]
39. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798 [TBL] [Abstract][Full Text] [Related]
40. Cancer vaccine field gets shot of optimism from positive results. Brower V Nat Med; 2005 Apr; 11(4):360. PubMed ID: 15812502 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]